| 摘要: |
| 目的:探讨选用华蟾素微球联合顺铂以及阿霉素经肝动脉化学栓塞对肝癌患者进行治疗的效果及预后。方法:选取2018年10月—2019年10月本院收治的60例肝癌患者，按随机数字表分为两组，给予对照组(30例)患者顺铂联合阿霉素经肝动脉化学栓塞治疗，给予观察组(30例)患者华蟾素微球+顺铂+阿霉素经肝动脉化学栓塞治疗，观察患者肝功能、生存率、总疗效以及不良反应、外围血T淋巴细胞亚群变化情况等。结果:治疗后，观察组ALT、AST、TBIL水平较对照组优，差异有统计学意义(t=2.634、2.509、3.196，P＜0.05)，两组患者ALP水平差异无统计学意义(t=0.262，P＞0.05)；观察组患者3个月、6个月、9个月以及1年的生存率均高于对照组，差异统计学意义(χ2=10.755、10.800、10.000、9.773，P＜0.05)；两组疗效分别为76.66%、46.66%，观察组显著更高(P＜0.05)；不良反应总发生率分别为10.00%、33.33%，观察组显著更低(P＜0.05)；观察组CD3+及CD4+比例较治疗前与对照组高(P＜0.05)， CD8+与对照组相差不大(P＞0.05)。结论:华蟾素微球联合顺铂、阿霉素经肝动脉化学栓塞方案治疗肝癌患者，可有效改善患者肝功能，提升其生存率与免疫功能，且不良反应发生率相对较低，临床疗效及预后较佳，值得推广。 |
| 关键词: 肝癌 华蟾素微球 顺铂 肝动脉化学栓塞 阿霉素 疗效 |
| DOI：10.3969/j.issn.1007-6948.2021.03.002 |
| 投稿时间：2020-08-29 |
| 基金项目: |
|
| Efficacy and Prognosis of Cinobufacini Microspheres Combined with Cisplatin Chemoembolization and Doxorubicin in the Treatment of Hepatocellular Carcinoma |
| JIANG Yang,HE Xian-lu,XIA Xu-liang |
| Hepatobiliary Vessels Department,The Second Affiliated Hospital of Chengdu Medical College · Nuclear Industry 416 Hospital, Chengdu610051,China |
| Abstract: |
| Objective To evaluate the efficacy and prognosis of Cinobufacini microsphere combined with CISPLATIN and doxorubicin in transcatheter arterial chemoembolization (TACE) for hepatocellular Carcinoma (HCC). Methods 60 patients with liver cancer admitted to our hospital from October 2018 to October 2019 were randomly divided into two groups. The patients in the control group (30 cases) were treated by TACE with doxorubicin and CISPLATIN, after TACE with Cinobufotalin microsphere + CISPLATIN + doxorubicin in 30 patients in the observation group. The liver function, survival rate, total efficacy, adverse reaction and peripheral blood T lymphocyte were observed. Results After treatment, the levels of ALT, AST and TBIL in the observation group were better than those in the control group (t=2.634, 2.509, 3.196, P<0.05) and there was no statistical significance (t=0.262, P>0.05). After treatment, the survival rates of the patients in the observation group at 3,6,9 months and 1 year were significantly higher than those in the control group and there were statistical significance (χ2 =10.755,10.800,10.000,9.773, P<0.05). After treatment, the curative effect of the two groups was 76.66%, 46.66% respectively, which the observation group was significantly higher. The total incidence of adverse reactions were 10.00%, 33.33% respectively, which the observation group was significantly lower (P<0.05). After treatment, the ratio of CD3+ and CD4+ in the observation group was higher than that in the control group before treatment (P <0.05), and the change of CD8+ in the control group was not significant (P>0.05). Conclusion Cinobufacini microsphere combined with CISPLATIN and doxorubicin can effectively improve the level of liver function index, improve the survival rate and immune function of patients with liver cancer, and the incidence of adverse reactions is relatively low. It has higher safety, better clinical curative effect and disease prognosis effect, which is worth popularizing. |
| Key words: Hepatocellular carcinoma cinobufotalin microspheres CISPLATIN chemoembolization of hepatic artery adriamycin ef?cacy |
